our technology platform leverages patented biodegradable functionalized nanoparticles (f-NPs) and a proprietary coating process developed at Cleveland Clinic to enhance drug uptake and retention into a cell.
Vinod Labhasetwar, PhD Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic
Efficient balloon-to-tissue drug uptake
No particle release during handling
Particle retention inside the cell
Sustained controlled release
Vinod Labhasetwar has an amazing memory. During his medical school years, he read a few articles about nanotechnology. At the time, nanotechnology in medical applications was only theoretical. Fast-forward to 1990, when Dr. Labhasetwar was studying cardiology at the University of Michigan. He remembered those articles on nanotechnology and developed his own theories. Since that time, he has devoted his life’s work to finding medical applications for nanotechnology, especially as it relates to cancer and cardiovascular diseases.
In 2017, Dr. Labhasetwar attended a GCIC conference presentation given by Marwan Berrada-Sounni. He was impressed with Berrada-Sounni’s understanding of nanotechnology and pleased to learn that he was interested in commercializing the technology. When Advanced NanoTherapies was launched, Dr. Labhasetwar was able to accelerate the development of nanotechnology for cardiovascular and endovascular applications.
Advanced NanoTherapies is currently focused on the urgent need for cardiovascular and endovascular applications to bring a safer therapeutic option to peripheral artery disease (PAD) patients using Sirolimus-coated angioplasty balloons. The technology has implications for many other applications, such as coronary and peripheral in-stent restenosis, a below-the-knee tibial disease in CLI, and dialysis A.V. graft treatment.